EUROPE: FORECAST FOR HIGH-PERFORMANCE FIBRES

Article Abstract:

A study by Frost & Sullivan predicts the demand for high-performance fibres in Europe to grow 2.5% in 1999 and 2.2% in 2000 from US$ 1.62bn in 1998. By 2005 the market is expected to reach US$ 1.95bn. At the end of the period, the growth rate is likely to reach 2.5%. However, the situation in the market is forecast to remain difficult for the next few years. Competition takes place mainly in price terms, as the products are largely generic. Also, there is overcapacity in the market. While the automotive industry is the main user of high-performance fibres, growth in this segment is forecast to slow down. Beside automotive applications such as airbags, strong growth is expected in the field of geotextiles. Most other application sectors are expected to grow, albeit less rapidly. In terms of materials, the steepest growth rates are expected for aramide fibres.

European Union, Noncellulosic Organic Fiber Manufacturing, Synthetic Fibers

---

EUROPE: FORECAST FOR PHARMACEUTICAL CHEMICALS

Article Abstract:

A study by The Freedonia Group predicts the European market for pharmaceutical chemicals to grow at an annual rate of 6.6% from US$ 9.32bn in 1997 to US$ 12.85bn in 2002. Steepest growth is expected in anti-infection chemicals, at 8.1% annually to US$ 1.09bn, followed by hormone products at 7.7% to US$ 1.15bn. Growth in chemicals for cardio-vascular drugs is estimated at 7.1% to US$ 2bn, central nervous system 6.3% to US$ 2.92bn, biological substances such as vaccines and blood constituents 6.1% to US$ 1.09bn and other pharmaceutical chemicals 5.8% to US$ 3.71bn.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs

---

EUROPE: MARKET POTENTIAL FOR ANTIHYPERTONICS

Article Abstract:

In 1997, the European market for anti-hypertensive medicines had a volume of US$ 8.10bn. Frost & Sullivan anticipates the demand to increase to US$ 8.60bn in 1998 and to US$ 9.31bn in 1999. Double-digit growth rates are expected after the change of the millennium, resulting in a market volume of US$ 18.17bn in 2004. There are about 150 pharmaceutical companies competing in the antihypertonics market. The European market leader is Merck Sharp & Dohme.

Pharmaceutical Preparation Manufacturing, Cardiovascular Preparations, Cardiovascular agents

Similar abstracts:

• Abstracts: FRANCE: DUPONT PERFORMANCE COATING CHANGES STATUS. FRANCE: CERI ANTIROUILLE CHANGES BOSS. FRANCE: NEW HQ FOR AKZO NOBEL INDUSTRIAL COATINGS
• Abstracts: GREECE/POLAND: NEW LINDE PLANTS FOR LIQUID GASES. GERMANY: SIEMENS USES ARGON FOR INERTING. POLAND/SLOVAKIA: NEW UNITS FOR GERMAN FIRMS
• Abstracts: GERMANY: SKW TROSTBERG BOOSTS BIOTECH R&D. GERMANY: PARTNER SOUGHT FOR PLASTIC INVENTION
• Abstracts: TURKEY: LURGI ENTSORGUNG TO SET UP PLANT. GERMANY: BYK GULDEN, BAYER GASTROENTEROLOGY DEAL. GERMANY: MORE CARBONIC ACID FROM RUHRCHEMIE
• Abstracts: NETHERLANDS: DEEGE CONCENTRATES PAINT PRODUCTION. GERMANY/FINLAND: HESSE, TIKKURILA MARKETING DEAL. GERMANY: NEW COATING TO PROTECT CONCRETE

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.